ADCendo ApS

Some forms of cancer remain without effective therapies despite decades of progress in oncology. For patients facing tumors with unmet clinical needs, the search for new treatment options is an absolute priority. ADCendo was founded with the goal of developing targeted therapies for these cancers, using the platform of antibody-drug conjugates — known as ADCs. ADCs are a class of oncology drugs that combine the precision of monoclonal antibodies — capable of selectively recognizing cancer cells — with the cytotoxic power of a chemotherapy agent. The concept is to deliver the therapeutic payload directly to the target cell, reducing exposure of healthy tissue while increasing treatment efficacy. This approach has already produced drugs approved by the FDA and EMA, but significant opportunity remains to explore ADCs in tumor types where no effective options yet exist. ADCendo focuses on oncology indications with high unmet clinical need, building a therapeutic pipeline around this technology. The operational structure involves collaboration with oncology centers and pharmaceutical partners who can support clinical development and commercialization, following a model typical of development-stage biotech companies. ADCendo's profile is that of an early-stage biotech focused on the research and development of innovative oncology drugs. The precision oncology market is one of the most attractive and competitive segments in pharmaceuticals, but also one in which technological innovation has the greatest potential to generate meaningful clinical and commercial value — particularly in indications where the current standard of care remains inadequate.